Denosumab Decreases Cortical Porosity in Postmenopausal Women with Low Bone Mineral Density

被引：0
|
作者：
Libanati, C. [1 ]
Boyd, S. K. [2 ]
Nishiyama, K. K. [2 ]
Zebaze, R. M.
Hanley, D. A. [2 ]
Zanchetta, J. R. [3 ]
Thomas, Thierry [4 ,5 ]
Boutroy, S. [6 ,7 ]
Bogado, C. E. [3 ]
Austin, M. [1 ]
Seeman, E. [8 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
[2] Univ Calgary, Calgary, AB, Canada
[3] Inst Invest Metabol, Buenos Aires, DF, Argentina
[4] Univ Hosp, St Etienne, France
[5] INSERM, U1059, St Etienne, France
[6] Univ Lyon, Lyon, France
[7] INSERM, U831, F-69008 Lyon, France
[8] Univ Melbourne, Austin & Repatriat Med Ctr, Melbourne, Vic, Australia
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1631
引用
收藏
页码：S637 / S638
页数：2
相关论文
共 50 条
  • [1] DENOSUMAB DECREASES CORTICAL POROSITY IN POSTMENOPAUSAL WOMEN WITH LOW BONE MINERAL DENSITY
    Zebaze, R. M.
    Boyd, S. K.
    Nishiyama, K. K.
    Hanley, D. A.
    Zanchetta, J. R.
    Thomas, T.
    Boutroy, S.
    Bogado, C.
    Austin, M.
    Libanati, C.
    Seeman, E.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : S527 - S527
  • [2] Denosumab decreases cortical porosity in postmenopausal women with low BMD
    Boyd, S. K.
    Nishiyama, K. K.
    Zebaze, R. M.
    Hanley, D. A.
    Zanchetta, J. R.
    Thomas, T.
    Boutroy, S.
    Bogado, C.
    Austin, M.
    Libanati, C.
    Seeman, E.
    BONE, 2011, 48 : S182 - S182
  • [3] Denosumab in postmenopausal women with low bone mineral density
    McClung, MR
    Lewiecki, EM
    Cohen, SB
    Bolognese, MA
    Woodson, GC
    Moffett, AH
    Peacock, M
    Miller, PD
    Lederman, SN
    Chesnut, CH
    Lain, D
    Kivitz, AJ
    Holloway, DL
    Zhang, C
    Peterson, MC
    Bekker, PJ
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08): : 821 - 831
  • [4] Denosumab in postmenopausal women with low bone mineral density
    Schwartzman, Julie
    Yazici, Yusuf
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (22): : 2390 - 2390
  • [5] Denosumab in postmenopausal women with low bone mineral density
    Charles L. Loprinzi
    Current Oncology Reports, 2006, 8 (4) : 267 - 268
  • [6] Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
    Chen, Yi
    Zhu, Jun
    Zhou, Yiqin
    Peng, Jinhui
    Wang, Bo
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [7] Effects of denosumab on bone mineral density and bone turnover in postmenopausal women
    Bone, Henry G.
    Bolognese, Michael A.
    Yuen, Chui Kin
    Kendler, David L.
    Wang, Huei
    Liu, Yu
    Martin, Javier San
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (06): : 2149 - 2157
  • [8] Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women
    Wensel, Terri M.
    Iranikhah, Maryam M.
    Wilborn, Teresa W.
    PHARMACOTHERAPY, 2011, 31 (05): : 510 - 523
  • [9] Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis
    Zhou, Zhenyu
    Chen, Chen
    Zhang, Jun
    Ji, Xinran
    Liu, Lifeng
    Zhang, Guichun
    Cao, Xuecheng
    Wang, Pingshan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (05): : 2113 - 2122
  • [10] DENOSUMAB FOLLOWING LONG-TERM ALENDRONATE IN POSTMENOPAUSAL WOMEN WITH LOW BONE MINERAL DENSITY
    Kendler, David L.
    Roux, Christian
    Benhamou, Claude-Laurent
    Brown, Jacques P.
    Lillestol, Mike
    Siddhanti, Suresh
    Man, Hoi-Shen
    San Martin, Javier
    Bone, Henry G.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : S215 - S215
12345